EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Pharmacokinetic Model of Vitamin D3 and Metabolites in Chronic Kidney Disease Patients with Vitamin D Insufficiency and Deficiency

Stacey M Tuey, Avisek Ghimire, Serge Guzy, Linda Prebehalla iD, Amandla-Atilano Roque, Gavriel Roda, Raymond E West, Michel B Chonchol, Nirav Shah, Thomas D Nolin iD, Melanie S Joy

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252212279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Stacey M Tuey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Vitamin D Deficiency, Cholecalciferol. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCATS NIH HHS, NIH R01.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitamin D insufficiency and deficiency are highly prevalent in patients with chronic kidney disease (CKD), and their pharmacokinetics are not well described. The primary study objective was to develop a population pharmacokinetic model of oral cholecalciferol (VitD3) and its three major metabolites, 25-hydroxyvitamin D3 (25D3), 1,25-dihydroxyvitamin D3 (1,25D3), and 24,25-dihydroxyvitamin D3 (24,25D3), in CKD patients with vitamin D insufficiency and deficiency. CKD subjects (n = 29) were administered one dose of oral VitD3 (5000 I.U.), and nonlinear mixed effects modeling was used to describe the pharmacokinetics of VitD3 and its metabolites. The simultaneous fit of a two-compartment model for VitD3 and a one-compartment model for each metabolite represented the observed data. A proportional error model explained the residual variability for each compound. No assessed covariate significantly affected the pharmacokinetics of VitD3 and metabolites. Visual predictive plots demonstrated the adequate fit of the pharmacokinetic data of VitD3 and metabolites. This is the first reported population pharmacokinetic modeling of VitD3 and metabolites and has the potential to inform targeted dose individualization strategies for therapy in the CKD population. Based on the simulation, doses of 600 International Unit (I.U.)/day to 1000 I.U./day for 6 months are recommended to obtain the target 25D3 concentration of between 30 and 60 ng/mL. These simulation findings could potentially contribute to the development of personalized dosage regimens for vitamin D treatment in patients with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicVitamin D DeficiencyCholecalciferolHumansMaleFemaleMiddle AgedAgedAdultModels, BiologicalCalcifediolAdministration, Oral

Stichwörter der Autor:innen

cholecalciferolchronic kidney diseasepopulation pharmacokinetic modelvitamin D deficiency

Substanzen

CholecalciferolCalcifediol

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO 80045, USA.
  • Pop-Pharm Pharmacometrics Service, Albany, CA 94706, USA.
  • Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO 80045, USA.
  • Department of Medicine Renal Electrolyte Division, University of Pittsburgh, Pittsburgh, PA 15261, USA.

ORCID-Profile: Linda Prebehalla, Thomas D Nolin

Förderung

  • NIGMS NIH HHS
  • NCATS NIH HHS
  • NIH R01
  • National Institute of Health (NIH)
  • Clinical and Translational Science Award (CTSA)
  • University of Colorado
  • University of Pittsburgh

Zitieren

APA

Tuey, S. M., Ghimire, A., Guzy, S., Prebehalla, L., Roque, A. A., Roda, G., West, R. E., Chonchol, M. B., Shah, N., Nolin, T. D., & Joy, M. S. (2024). Population Pharmacokinetic Model of Vitamin D3 and Metabolites in Chronic Kidney Disease Patients with Vitamin D Insufficiency and Deficiency. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212279

Vancouver

Tuey SM, Ghimire A, Guzy S, Prebehalla L, Roque AA, Roda G, et al. Population Pharmacokinetic Model of Vitamin D3 and Metabolites in Chronic Kidney Disease Patients with Vitamin D Insufficiency and Deficiency. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212279

BibTeX
@article{Tuey2024,
  author = {Tuey, Stacey M and Ghimire, Avisek and Guzy, Serge and Prebehalla, Linda and Roque, Amandla-Atilano and Roda, Gavriel and West, Raymond E and Chonchol, Michel B and Shah, Nirav and Nolin, Thomas D and Joy, Melanie S},
  title = {Population Pharmacokinetic Model of Vitamin D3 and Metabolites in Chronic Kidney Disease Patients with Vitamin D Insufficiency and Deficiency},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252212279}
}
Kostenlos starten →